Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of ivacaftor (VX-770) on lung clearance
index (LCI) in subjects aged 6 years and older with cystic fibrosis (CF) who have the
G551D-CFTR mutation on at least 1 allele.
Phase:
Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics